Full-Time

Senior Manager of Portfolio V&a Insights

Posted on 5/31/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$173.8k - $204.8k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Remote in USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Requirements
  • Doctorate degree and 2 years of pricing, functional lead experience, and/or sales / marketing operations experience
  • Master’s degree and 4 years of pricing, functional lead experience, and/or sales / marketing operations experience
  • Bachelor’s degree and 6 years of pricing, functional lead experience, and/or sales / marketing operations experience
  • Associate’s degree and 10 years of pricing, functional lead experience, and/or sales / marketing operations experience
  • High school diploma / GED and 12 years pricing, functional lead experience, and/or sales / marketing operations experience
Responsibilities
  • Manage US pricing governance process for new launches, WAC changes and contract platform updates, including managing timelines and task list, preparing for Pricing Committee meetings, and documentation and recordkeeping of meeting minutes
  • Assist with ad hoc cross-functional analyses across the US portfolio and report findings with senior leadership
  • Serve as the functional lead for Anaplan channel forecasting across the US portfolio
  • Translate of Coverage and Pricing (C&P) team needs to the Digital, Technology and Innovation (DTI) team to ensure updates and builds meet requirements
  • Onboard new C&P teams to Anaplan use and support new product integration into the platform
  • Serve as a liaison with the other platforms in the GTN initiatives to ensure Anaplan considerations are represented
  • Serve as an Anaplan platform subject matter expert to support Amgen’s quarterly Latest Estimate Discount Rate (LEDR) cycles across the finance, C&P and accounting teams
  • Lead other USVA governance on an “as needed" basis
Desired Qualifications
  • 6+ years of experience solving complex business problems and representing business needs to technical teams
  • Strong track record of critical thinking and successful implementation of initiatives within the Biotech or Pharmaceutical industry
  • Excellent oral, written and presentation skills with ability to explain complex concepts clearly to a variety of audiences, including senior and executive management
  • Demonstrated track record of increasing responsibility and leadership experience
  • Excellent project management skills and capacity to manage/lead multiple projects
  • Ability to work cross-functionally across USV&A, DTI / IS, Legal, Finance and Accounting
  • Effective communicator and demonstrate success in a matrix environment both as a leader and member of cross-functional teams
  • Ability to manage multiple projects with varying priorities

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen emphasizes biologic therapies and reinvests a large portion of its earnings back into R&D. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

INACTIVE